There are currently 980 clinical trials in Tampa, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Moffitt Cancer Center, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate Leramistat in Patients With IPF
NCT05951296
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: GCP Clinical Research, LLC, Tampa, Florida +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
NCT06011577
Recruiting
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/15/2024
Locations: Relmada Site, Tampa, Florida +1 locations
Conditions: Major Depressive Disorder, Depression
Register for Updates
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
NCT04855747
Recruiting
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/15/2024
Locations: Relmada Site, Tampa, Florida +2 locations
Conditions: Major Depressive Disorder, Depression
Register for Updates
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
NCT02681549
Recruiting
The purpose of this phase 2 trial is to study the activity of pembrolizumab in combination with bevacizumab in patients with untreated brain metastases from melanoma or NSCLC to determine activity and safety of the drug combination. Furthermore, in patients who undergo resection of biopsy of a brain metastasis, we will evaluate biomarkers predictive of treatment benefit, and will also conduct correlative biomarker studies on extra-cerebral specimens in all patients in whom a systemic biopsy is f... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Melanoma, Non-small Cell Lung Cancer, Brain Metastasis
Register for Updates
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
NCT05197270
Recruiting
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment
Gender:
All
Ages:
50 years and above
Trial Updated:
02/15/2024
Locations: Retina Vitreous Associates of Florida, Tampa, Florida
Conditions: Neovascular (Wet) Age-Related Macular Degeneration
Register for Updates
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
NCT04748601
Recruiting
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
Gender:
All
Ages:
Between 6 years and 11 years
Trial Updated:
02/14/2024
Locations: Upsher-Smith Clinical Trial Site #14, Tampa, Florida
Conditions: Migraine Disorders
Register for Updates
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
NCT05375084
Recruiting
This is a Phase 1 study of BBP-398, a SHP2 inhibitor, in combination with nivolumab, a PD-1 antibody, in patients with NSCLC with a KRAS mutation. The study involves 2 parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Non Small Cell Lung Cancer, Solid Tumor
Register for Updates
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
NCT05589896
Recruiting
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute leukemias. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
02/14/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia
Register for Updates
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
NCT05271630
Recruiting
The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/13/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
NCT05177211
Recruiting
The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/13/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Myeloproliferative Neoplasm, Chronic Neutrophilic Leukemia, MDS
Register for Updates
Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board
NCT04343365
Recruiting
This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
Gender:
All
Ages:
All
Trial Updated:
02/13/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Incurable Disease
Register for Updates
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
NCT05189457
Recruiting
The goal of this clinical research is to find if sequential therapy with combined androgen deprivation or hormonal therapy with luteinizing hormone release hormone (LHRH) analog plus a new hormonal agent (abiraterone, enzalutamide, or apalutamide) followed by chemohormonal therapy with docetaxel and LHRH analog would improve the outcome of high risk metastatic/stage IV prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/13/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Prostate Cancer, Stage IV Prostate Cancer
Register for Updates